Other Deals Are Up 3400% in 2026 — Here's the Data

Thirty-four deals in six months — up from zero in the prior period. That's a 3400% surge in other deal trends 2026, covering transactions that fall outside conventional therapeutic area classifications: platform technologies, enabling tools, diagnostics-adjacent assets, and cross-sector licensing. The driver is unmistakable: Big Pharma is no longer just buying molecules. It's buying infrastructure.

The Data — Other Deal Activity, Period over Period

This isn't a gradual acceleration — it's a phase change. The prior six-month window (August 2025 through February 2026) registered zero qualifying deals in this category. Then, starting in late Q1 2026, the floodgates opened. The 34 transactions recorded between February and August 2026 span acquisitions, other licensing 2026 arrangements, and platform-level partnerships that defy traditional TA classification. When you see a dataset go from zero to 34, something structural shifted in how BD teams are defining "strategic fit."

What's Driving the Trend

Three forces converged to produce this spike. First, the biologics manufacturing bottleneck hit critical mass. After years of CDMOs struggling to meet demand, pharma companies started vertically integrating — not by building plants, but by acquiring the enabling technology stack. Bio-Techne's protein sciences, reagent platforms, and bioprocessing tools became the most visible target. When Merck KGaA paid $11.3B for Bio-Techne Corporation, it wasn't buying a therapeutic pipeline. It was buying the picks and shovels for the next decade of biologic and cell therapy manufacturing. That deal alone reshaped how the market values platform companies.

Second, generative biology arrived as a dealmaking category. Generate: Biomedicines' partnership with Novartis in late June 2026 is the clearest signal yet that AI-native drug design companies have crossed the credibility threshold with Big Pharma. These aren't traditional licensing deals with defined molecules — they're capability acquisitions. Novartis is paying for the engine, not the output. This represents a philosophical break from the molecule-centric BD model that dominated the previous two decades.

Third, geographic arbitrage deals accelerated. Pfizer's $2.05B total deal value agreement with YaoPharma, structured with a $150M upfront, follows the playbook of Western pharma companies licensing Chinese-originated assets or distribution capabilities at valuations that remain discounted relative to US-originated deals. Capital availability in China's biotech sector tightened further in early 2026, creating a buyer's market for well-positioned Western acquirers. Pfizer moved decisively. Expect more of these cross-border structures through year-end.

Notable Deals

The Bio-Techne/Merck KGaA deal dominates this dataset — and it should. At $11.3B, it's one of the largest platform-technology acquisitions in biopharma history. The multiple entries in the table reflect the deal's complexity: the transaction was structured across multiple closing tranches and entity-level transfers, which is typical for acquisitions of this scale involving a publicly traded target. What matters for benchmarking purposes is the $11.3B TDV, which represents roughly 8.5x Bio-Techne's trailing twelve-month revenue — a premium justified only if Merck KGaA can capture significant synergies across its Life Science division. Compare that to Danaher's 2019 acquisition of GE Biopharma at roughly 17x revenue; Merck KGaA got a better price, reflecting the tighter capital environment. You can evaluate how this stacks against current multiples using Deal Benchmarks on the Ambrosia platform.

The Generate: Biomedicines/Novartis deal is harder to value because financial terms weren't disclosed, but the signal is clear. Novartis, which has historically been conservative about AI-driven drug design partnerships, made a public commitment to a generative biology platform. The absence of disclosed financials suggests either a complex equity-plus-milestones structure or a strategic collaboration with option rights — both of which point to Novartis wanting optionality rather than a defined asset. For biotech founders building platform companies, this deal validates a fundraising and BD narrative that was still speculative 18 months ago.

YaoPharma's $150M upfront from Pfizer — with $2.05B in total deal value — represents a 7.3% upfront-to-TDV ratio. That's lean by 2026 standards, where the median upfront-to-TDV ratio for other licensing 2026 deals has trended toward 12-15% based on Deal Benchmarks data. Either Pfizer negotiated aggressively, or the milestone structure is heavily back-loaded on commercial targets that reflect genuine risk-sharing. BD teams evaluating China-to-West licensing structures should use this as a floor, not a ceiling.

What This Means for BD Teams Right Now

If you're selling a platform technology or enabling-infrastructure asset: this is your market. The 3400% deal surge isn't evenly distributed — it's concentrated in Q2 2026, with 34 deals compressed into essentially a four-month window. That velocity creates urgency on the buy side and leverage on the sell side. Big Pharma pipeline gaps in traditional TA categories (oncology, immunology) are well-documented, but the emerging gap is in capabilities: manufacturing tech, AI-native design, and geographic market access. If your asset fills one of those gaps, you have more potential counterparties today than at any point in the last five years.

If you're buying, move fast but structure carefully. The Bio-Techne deal shows that platform acquisitions command premium multiples even in a tighter macro environment. Waiting for valuations to soften is a losing strategy when 34 deals just landed in a category that had zero activity six months ago — the competitive dynamics are shifting week by week. That said, the YaoPharma deal structure offers a template for disciplined buyers: modest upfront, milestone-heavy, with commercial-stage gates that protect downside. Use Solidus to model the upfront-to-TDV ratios and milestone structures that match your risk appetite.

Deal structures gaining favor in this category: hybrid acquisition-plus-licensing frameworks (Merck KGaA), option-based platform collaborations (Novartis), and back-loaded milestone structures for cross-border deals (Pfizer). Pure upfront-heavy term sheets are losing ground — buyers want optionality, and sellers are accepting it in exchange for higher total deal values.

Benchmark your deal against current market rates. Whether you're structuring an enabling-technology acquisition or a platform licensing deal, the Ambrosia calculator lets you stress-test your terms against the 34 transactions that defined other deal trends 2026.